Photodynamic therapy of head and neck basal cell carcinoma according to different clinicopathologic features.
OBJECTIVE
We aimed to treat different pathologic types of basal cell carcinomas (BCCs) using photodynamic therapy (PDT).


METHODS
Thirty lesions in six patients underwent PDT. The photosensitizer used was Photoheme, a hematoporphyrin derivative IX. It was injected intravenously at the dose of 2-3.25 mg/kg. After 24 hours, the lesions were illuminated by laser light (lambda = 632 nm, light exposure dose = 100-200 J/cm2). Lesions were evaluated pre and post-operatively and at follow-up sessions (of up to 6 months).


RESULTS
After a single session of PDT, the average response rate in different histopathologic kinds of basal cell carcinoma (e.g., ulcerative, superficial, nodular, and pigmented forms) were 100%, 62%, 90%, and 14%, respectively. In patients who responded completely, the cosmetic results were excellent and there were no recurrence at 6th month of follow-up.


CONCLUSIONS
Although PDT seems to be an effective treatment modality for superficial, ulcerative, and nodular BCCs, it is not recommended for pigmented lesions.
Kaviani
Ahmad
A
Tehran University of Medical Sciences and Iranian Center for Medical Laser Research, Tehran, Iran. akaviani@sina.tums.ac.ir
Ataie-Fashtami
Leila
L
Fateh
Mohsen
M
Sheikhbahaee
Nasim
N
Ghodsi
Maryam
M
Zand
Nasrin
N
Djavid
Gholamreza Esmaeeli
GE
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002280:Basal Cell Carcinoma / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017324:Hematoporphyrin Derivative / Q000008:administration & dosage / Q000627:therapeutic use*; D006414:Hematoporphyrin Photoradiation; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D017319:Photosensitizing Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
D017319:Photosensitizing Agents; D017324:Hematoporphyrin Derivative